

Global Urological Cancer Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/G72CB540F61CEN.html>

Date: June 2024

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: G72CB540F61CEN

Abstracts

According to our (Global Info Research) latest study, the global Urological Cancer Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The Global Info Research report includes an overview of the development of the Urological Cancer Drugs industry chain, the market status of Prostate Cancer (Tablets, Injection), Bladder Cancer (Tablets, Injection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Urological Cancer Drugs.

Regionally, the report analyzes the Urological Cancer Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Urological Cancer Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Urological Cancer Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Urological Cancer Drugs industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Pcs), revenue generated, and market share of different by Type (e.g., Tablets, Injection).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Urological Cancer Drugs market.

Regional Analysis: The report involves examining the Urological Cancer Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Urological Cancer Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Urological Cancer Drugs:

Company Analysis: Report covers individual Urological Cancer Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Urological Cancer Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Prostate Cancer, Bladder Cancer).

Technology Analysis: Report covers specific technologies relevant to Urological Cancer Drugs. It assesses the current state, advancements, and potential future developments in Urological Cancer Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Urological Cancer Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Urological Cancer Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type

Tablets

Injection

Market segment by Application

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Others

Major players covered

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A

Tolmar Inc

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Urological Cancer Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Urological Cancer Drugs, with price, sales, revenue and global market share of Urological Cancer Drugs from 2019 to 2024.

Chapter 3, the Urological Cancer Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Urological Cancer Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023. and Urological Cancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Urological Cancer Drugs.

Chapter 14 and 15, to describe Urological Cancer Drugs sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Urological Cancer Drugs
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Urological Cancer Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
 - 1.3.2 Tablets
 - 1.3.3 Injection
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Urological Cancer Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
 - 1.4.2 Prostate Cancer
 - 1.4.3 Bladder Cancer
 - 1.4.4 Kidney Cancer
 - 1.4.5 Testicular Cancer
 - 1.4.6 Others
- 1.5 Global Urological Cancer Drugs Market Size & Forecast
 - 1.5.1 Global Urological Cancer Drugs Consumption Value (2019 & 2023 & 2030)
 - 1.5.2 Global Urological Cancer Drugs Sales Quantity (2019-2030)
 - 1.5.3 Global Urological Cancer Drugs Average Price (2019-2030)

2 MANUFACTURERS PROFILES

- 2.1 Novartis
 - 2.1.1 Novartis Details
 - 2.1.2 Novartis Major Business
 - 2.1.3 Novartis Urological Cancer Drugs Product and Services
 - 2.1.4 Novartis Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.1.5 Novartis Recent Developments/Updates
- 2.2 Pfizer
 - 2.2.1 Pfizer Details
 - 2.2.2 Pfizer Major Business
 - 2.2.3 Pfizer Urological Cancer Drugs Product and Services
 - 2.2.4 Pfizer Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

- 2.2.5 Pfizer Recent Developments/Updates
- 2.3 Johnson & Johnson
 - 2.3.1 Johnson & Johnson Details
 - 2.3.2 Johnson & Johnson Major Business
 - 2.3.3 Johnson & Johnson Urological Cancer Drugs Product and Services
 - 2.3.4 Johnson & Johnson Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.3.5 Johnson & Johnson Recent Developments/Updates
- 2.4 AstraZeneca
 - 2.4.1 AstraZeneca Details
 - 2.4.2 AstraZeneca Major Business
 - 2.4.3 AstraZeneca Urological Cancer Drugs Product and Services
 - 2.4.4 AstraZeneca Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.4.5 AstraZeneca Recent Developments/Updates
- 2.5 Astellas
 - 2.5.1 Astellas Details
 - 2.5.2 Astellas Major Business
 - 2.5.3 Astellas Urological Cancer Drugs Product and Services
 - 2.5.4 Astellas Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.5.5 Astellas Recent Developments/Updates
- 2.6 Bristol-Myers Squibb
 - 2.6.1 Bristol-Myers Squibb Details
 - 2.6.2 Bristol-Myers Squibb Major Business
 - 2.6.3 Bristol-Myers Squibb Urological Cancer Drugs Product and Services
 - 2.6.4 Bristol-Myers Squibb Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.6.5 Bristol-Myers Squibb Recent Developments/Updates
- 2.7 Abbott Laboratories
 - 2.7.1 Abbott Laboratories Details
 - 2.7.2 Abbott Laboratories Major Business
 - 2.7.3 Abbott Laboratories Urological Cancer Drugs Product and Services
 - 2.7.4 Abbott Laboratories Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.7.5 Abbott Laboratories Recent Developments/Updates
- 2.8 Celgene Corporation
 - 2.8.1 Celgene Corporation Details
 - 2.8.2 Celgene Corporation Major Business

- 2.8.3 Celgene Corporation Urological Cancer Drugs Product and Services
- 2.8.4 Celgene Corporation Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Celgene Corporation Recent Developments/Updates
- 2.9 Dendreon Corporation
 - 2.9.1 Dendreon Corporation Details
 - 2.9.2 Dendreon Corporation Major Business
 - 2.9.3 Dendreon Corporation Urological Cancer Drugs Product and Services
 - 2.9.4 Dendreon Corporation Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.9.5 Dendreon Corporation Recent Developments/Updates
- 2.10 Ferring Pharmaceuticals
 - 2.10.1 Ferring Pharmaceuticals Details
 - 2.10.2 Ferring Pharmaceuticals Major Business
 - 2.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Product and Services
 - 2.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.10.5 Ferring Pharmaceuticals Recent Developments/Updates
- 2.11 GlaxoSmithKline
 - 2.11.1 GlaxoSmithKline Details
 - 2.11.2 GlaxoSmithKline Major Business
 - 2.11.3 GlaxoSmithKline Urological Cancer Drugs Product and Services
 - 2.11.4 GlaxoSmithKline Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.11.5 GlaxoSmithKline Recent Developments/Updates
- 2.12 Indevus Pharmaceuticals Inc
 - 2.12.1 Indevus Pharmaceuticals Inc Details
 - 2.12.2 Indevus Pharmaceuticals Inc Major Business
 - 2.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product and Services
 - 2.12.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.12.5 Indevus Pharmaceuticals Inc Recent Developments/Updates
- 2.13 Ipsen
 - 2.13.1 Ipsen Details
 - 2.13.2 Ipsen Major Business
 - 2.13.3 Ipsen Urological Cancer Drugs Product and Services
 - 2.13.4 Ipsen Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.13.5 Ipsen Recent Developments/Updates

2.14 Roche Healthcare

2.14.1 Roche Healthcare Details

2.14.2 Roche Healthcare Major Business

2.14.3 Roche Healthcare Urological Cancer Drugs Product and Services

2.14.4 Roche Healthcare Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.14.5 Roche Healthcare Recent Developments/Updates

2.15 Sanofi S.A

2.15.1 Sanofi S.A Details

2.15.2 Sanofi S.A Major Business

2.15.3 Sanofi S.A Urological Cancer Drugs Product and Services

2.15.4 Sanofi S.A Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.15.5 Sanofi S.A Recent Developments/Updates

2.16 Tolmar Inc

2.16.1 Tolmar Inc Details

2.16.2 Tolmar Inc Major Business

2.16.3 Tolmar Inc Urological Cancer Drugs Product and Services

2.16.4 Tolmar Inc Urological Cancer Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.16.5 Tolmar Inc Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: UROLOGICAL CANCER DRUGS BY MANUFACTURER

3.1 Global Urological Cancer Drugs Sales Quantity by Manufacturer (2019-2024)

3.2 Global Urological Cancer Drugs Revenue by Manufacturer (2019-2024)

3.3 Global Urological Cancer Drugs Average Price by Manufacturer (2019-2024)

3.4 Market Share Analysis (2023)

3.4.1 Producer Shipments of Urological Cancer Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2023

3.4.2 Top 3 Urological Cancer Drugs Manufacturer Market Share in 2023

3.4.2 Top 6 Urological Cancer Drugs Manufacturer Market Share in 2023

3.5 Urological Cancer Drugs Market: Overall Company Footprint Analysis

3.5.1 Urological Cancer Drugs Market: Region Footprint

3.5.2 Urological Cancer Drugs Market: Company Product Type Footprint

3.5.3 Urological Cancer Drugs Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Urological Cancer Drugs Market Size by Region

4.1.1 Global Urological Cancer Drugs Sales Quantity by Region (2019-2030)

4.1.2 Global Urological Cancer Drugs Consumption Value by Region (2019-2030)

4.1.3 Global Urological Cancer Drugs Average Price by Region (2019-2030)

4.2 North America Urological Cancer Drugs Consumption Value (2019-2030)

4.3 Europe Urological Cancer Drugs Consumption Value (2019-2030)

4.4 Asia-Pacific Urological Cancer Drugs Consumption Value (2019-2030)

4.5 South America Urological Cancer Drugs Consumption Value (2019-2030)

4.6 Middle East and Africa Urological Cancer Drugs Consumption Value (2019-2030)

5 MARKET SEGMENT BY TYPE

5.1 Global Urological Cancer Drugs Sales Quantity by Type (2019-2030)

5.2 Global Urological Cancer Drugs Consumption Value by Type (2019-2030)

5.3 Global Urological Cancer Drugs Average Price by Type (2019-2030)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Urological Cancer Drugs Sales Quantity by Application (2019-2030)

6.2 Global Urological Cancer Drugs Consumption Value by Application (2019-2030)

6.3 Global Urological Cancer Drugs Average Price by Application (2019-2030)

7 NORTH AMERICA

7.1 North America Urological Cancer Drugs Sales Quantity by Type (2019-2030)

7.2 North America Urological Cancer Drugs Sales Quantity by Application (2019-2030)

7.3 North America Urological Cancer Drugs Market Size by Country

7.3.1 North America Urological Cancer Drugs Sales Quantity by Country (2019-2030)

7.3.2 North America Urological Cancer Drugs Consumption Value by Country (2019-2030)

7.3.3 United States Market Size and Forecast (2019-2030)

7.3.4 Canada Market Size and Forecast (2019-2030)

7.3.5 Mexico Market Size and Forecast (2019-2030)

8 EUROPE

- 8.1 Europe Urological Cancer Drugs Sales Quantity by Type (2019-2030)
- 8.2 Europe Urological Cancer Drugs Sales Quantity by Application (2019-2030)
- 8.3 Europe Urological Cancer Drugs Market Size by Country
 - 8.3.1 Europe Urological Cancer Drugs Sales Quantity by Country (2019-2030)
 - 8.3.2 Europe Urological Cancer Drugs Consumption Value by Country (2019-2030)
 - 8.3.3 Germany Market Size and Forecast (2019-2030)
 - 8.3.4 France Market Size and Forecast (2019-2030)
 - 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
 - 8.3.6 Russia Market Size and Forecast (2019-2030)
 - 8.3.7 Italy Market Size and Forecast (2019-2030)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Urological Cancer Drugs Sales Quantity by Type (2019-2030)
- 9.2 Asia-Pacific Urological Cancer Drugs Sales Quantity by Application (2019-2030)
- 9.3 Asia-Pacific Urological Cancer Drugs Market Size by Region
 - 9.3.1 Asia-Pacific Urological Cancer Drugs Sales Quantity by Region (2019-2030)
 - 9.3.2 Asia-Pacific Urological Cancer Drugs Consumption Value by Region (2019-2030)
 - 9.3.3 China Market Size and Forecast (2019-2030)
 - 9.3.4 Japan Market Size and Forecast (2019-2030)
 - 9.3.5 Korea Market Size and Forecast (2019-2030)
 - 9.3.6 India Market Size and Forecast (2019-2030)
 - 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
 - 9.3.8 Australia Market Size and Forecast (2019-2030)

10 SOUTH AMERICA

- 10.1 South America Urological Cancer Drugs Sales Quantity by Type (2019-2030)
- 10.2 South America Urological Cancer Drugs Sales Quantity by Application (2019-2030)
- 10.3 South America Urological Cancer Drugs Market Size by Country
 - 10.3.1 South America Urological Cancer Drugs Sales Quantity by Country (2019-2030)
 - 10.3.2 South America Urological Cancer Drugs Consumption Value by Country (2019-2030)
 - 10.3.3 Brazil Market Size and Forecast (2019-2030)
 - 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Urological Cancer Drugs Sales Quantity by Type (2019-2030)

- 11.2 Middle East & Africa Urological Cancer Drugs Sales Quantity by Application (2019-2030)
- 11.3 Middle East & Africa Urological Cancer Drugs Market Size by Country
 - 11.3.1 Middle East & Africa Urological Cancer Drugs Sales Quantity by Country (2019-2030)
 - 11.3.2 Middle East & Africa Urological Cancer Drugs Consumption Value by Country (2019-2030)
 - 11.3.3 Turkey Market Size and Forecast (2019-2030)
 - 11.3.4 Egypt Market Size and Forecast (2019-2030)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
 - 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 MARKET DYNAMICS

- 12.1 Urological Cancer Drugs Market Drivers
- 12.2 Urological Cancer Drugs Market Restraints
- 12.3 Urological Cancer Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Urological Cancer Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Urological Cancer Drugs
- 13.3 Urological Cancer Drugs Production Process
- 13.4 Urological Cancer Drugs Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Urological Cancer Drugs Typical Distributors
- 14.3 Urological Cancer Drugs Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Urological Cancer Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Urological Cancer Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Novartis Basic Information, Manufacturing Base and Competitors

Table 4. Novartis Major Business

Table 5. Novartis Urological Cancer Drugs Product and Services

Table 6. Novartis Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 7. Novartis Recent Developments/Updates

Table 8. Pfizer Basic Information, Manufacturing Base and Competitors

Table 9. Pfizer Major Business

Table 10. Pfizer Urological Cancer Drugs Product and Services

Table 11. Pfizer Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 12. Pfizer Recent Developments/Updates

Table 13. Johnson & Johnson Basic Information, Manufacturing Base and Competitors

Table 14. Johnson & Johnson Major Business

Table 15. Johnson & Johnson Urological Cancer Drugs Product and Services

Table 16. Johnson & Johnson Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 17. Johnson & Johnson Recent Developments/Updates

Table 18. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 19. AstraZeneca Major Business

Table 20. AstraZeneca Urological Cancer Drugs Product and Services

Table 21. AstraZeneca Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 22. AstraZeneca Recent Developments/Updates

Table 23. Astellas Basic Information, Manufacturing Base and Competitors

Table 24. Astellas Major Business

Table 25. Astellas Urological Cancer Drugs Product and Services

Table 26. Astellas Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 27. Astellas Recent Developments/Updates

- Table 28. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
- Table 29. Bristol-Myers Squibb Major Business
- Table 30. Bristol-Myers Squibb Urological Cancer Drugs Product and Services
- Table 31. Bristol-Myers Squibb Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 32. Bristol-Myers Squibb Recent Developments/Updates
- Table 33. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
- Table 34. Abbott Laboratories Major Business
- Table 35. Abbott Laboratories Urological Cancer Drugs Product and Services
- Table 36. Abbott Laboratories Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 37. Abbott Laboratories Recent Developments/Updates
- Table 38. Celgene Corporation Basic Information, Manufacturing Base and Competitors
- Table 39. Celgene Corporation Major Business
- Table 40. Celgene Corporation Urological Cancer Drugs Product and Services
- Table 41. Celgene Corporation Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 42. Celgene Corporation Recent Developments/Updates
- Table 43. Dendreon Corporation Basic Information, Manufacturing Base and Competitors
- Table 44. Dendreon Corporation Major Business
- Table 45. Dendreon Corporation Urological Cancer Drugs Product and Services
- Table 46. Dendreon Corporation Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 47. Dendreon Corporation Recent Developments/Updates
- Table 48. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 49. Ferring Pharmaceuticals Major Business
- Table 50. Ferring Pharmaceuticals Urological Cancer Drugs Product and Services
- Table 51. Ferring Pharmaceuticals Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 52. Ferring Pharmaceuticals Recent Developments/Updates
- Table 53. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
- Table 54. GlaxoSmithKline Major Business
- Table 55. GlaxoSmithKline Urological Cancer Drugs Product and Services

Table 56. GlaxoSmithKline Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 57. GlaxoSmithKline Recent Developments/Updates

Table 58. Indevus Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors

Table 59. Indevus Pharmaceuticals Inc Major Business

Table 60. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product and Services

Table 61. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 62. Indevus Pharmaceuticals Inc Recent Developments/Updates

Table 63. Ipsen Basic Information, Manufacturing Base and Competitors

Table 64. Ipsen Major Business

Table 65. Ipsen Urological Cancer Drugs Product and Services

Table 66. Ipsen Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 67. Ipsen Recent Developments/Updates

Table 68. Roche Healthcare Basic Information, Manufacturing Base and Competitors

Table 69. Roche Healthcare Major Business

Table 70. Roche Healthcare Urological Cancer Drugs Product and Services

Table 71. Roche Healthcare Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 72. Roche Healthcare Recent Developments/Updates

Table 73. Sanofi S.A Basic Information, Manufacturing Base and Competitors

Table 74. Sanofi S.A Major Business

Table 75. Sanofi S.A Urological Cancer Drugs Product and Services

Table 76. Sanofi S.A Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 77. Sanofi S.A Recent Developments/Updates

Table 78. Tolmar Inc Basic Information, Manufacturing Base and Competitors

Table 79. Tolmar Inc Major Business

Table 80. Tolmar Inc Urological Cancer Drugs Product and Services

Table 81. Tolmar Inc Urological Cancer Drugs Sales Quantity (K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 82. Tolmar Inc Recent Developments/Updates

Table 83. Global Urological Cancer Drugs Sales Quantity by Manufacturer (2019-2024) & (K Pcs)

Table 84. Global Urological Cancer Drugs Revenue by Manufacturer (2019-2024) & (USD Million)

Table 85. Global Urological Cancer Drugs Average Price by Manufacturer (2019-2024) & (USD/Pcs)

Table 86. Market Position of Manufacturers in Urological Cancer Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023

Table 87. Head Office and Urological Cancer Drugs Production Site of Key Manufacturer

Table 88. Urological Cancer Drugs Market: Company Product Type Footprint

Table 89. Urological Cancer Drugs Market: Company Product Application Footprint

Table 90. Urological Cancer Drugs New Market Entrants and Barriers to Market Entry

Table 91. Urological Cancer Drugs Mergers, Acquisition, Agreements, and Collaborations

Table 92. Global Urological Cancer Drugs Sales Quantity by Region (2019-2024) & (K Pcs)

Table 93. Global Urological Cancer Drugs Sales Quantity by Region (2025-2030) & (K Pcs)

Table 94. Global Urological Cancer Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 95. Global Urological Cancer Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 96. Global Urological Cancer Drugs Average Price by Region (2019-2024) & (USD/Pcs)

Table 97. Global Urological Cancer Drugs Average Price by Region (2025-2030) & (USD/Pcs)

Table 98. Global Urological Cancer Drugs Sales Quantity by Type (2019-2024) & (K Pcs)

Table 99. Global Urological Cancer Drugs Sales Quantity by Type (2025-2030) & (K Pcs)

Table 100. Global Urological Cancer Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 101. Global Urological Cancer Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 102. Global Urological Cancer Drugs Average Price by Type (2019-2024) & (USD/Pcs)

Table 103. Global Urological Cancer Drugs Average Price by Type (2025-2030) & (USD/Pcs)

Table 104. Global Urological Cancer Drugs Sales Quantity by Application (2019-2024) & (K Pcs)

Table 105. Global Urological Cancer Drugs Sales Quantity by Application (2025-2030) & (K Pcs)

Table 106. Global Urological Cancer Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 107. Global Urological Cancer Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 108. Global Urological Cancer Drugs Average Price by Application (2019-2024) & (USD/Pcs)

Table 109. Global Urological Cancer Drugs Average Price by Application (2025-2030) & (USD/Pcs)

Table 110. North America Urological Cancer Drugs Sales Quantity by Type (2019-2024) & (K Pcs)

Table 111. North America Urological Cancer Drugs Sales Quantity by Type (2025-2030) & (K Pcs)

Table 112. North America Urological Cancer Drugs Sales Quantity by Application (2019-2024) & (K Pcs)

Table 113. North America Urological Cancer Drugs Sales Quantity by Application (2025-2030) & (K Pcs)

Table 114. North America Urological Cancer Drugs Sales Quantity by Country (2019-2024) & (K Pcs)

Table 115. North America Urological Cancer Drugs Sales Quantity by Country (2025-2030) & (K Pcs)

Table 116. North America Urological Cancer Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 117. North America Urological Cancer Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 118. Europe Urological Cancer Drugs Sales Quantity by Type (2019-2024) & (K Pcs)

Table 119. Europe Urological Cancer Drugs Sales Quantity by Type (2025-2030) & (K Pcs)

Table 120. Europe Urological Cancer Drugs Sales Quantity by Application (2019-2024) & (K Pcs)

Table 121. Europe Urological Cancer Drugs Sales Quantity by Application (2025-2030) & (K Pcs)

Table 122. Europe Urological Cancer Drugs Sales Quantity by Country (2019-2024) & (K Pcs)

Table 123. Europe Urological Cancer Drugs Sales Quantity by Country (2025-2030) & (K Pcs)

Table 124. Europe Urological Cancer Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 125. Europe Urological Cancer Drugs Consumption Value by Country

(2025-2030) & (USD Million)

Table 126. Asia-Pacific Urological Cancer Drugs Sales Quantity by Type (2019-2024) & (K Pcs)

Table 127. Asia-Pacific Urological Cancer Drugs Sales Quantity by Type (2025-2030) & (K Pcs)

Table 128. Asia-Pacific Urological Cancer Drugs Sales Quantity by Application (2019-2024) & (K Pcs)

Table 129. Asia-Pacific Urological Cancer Drugs Sales Quantity by Application (2025-2030) & (K Pcs)

Table 130. Asia-Pacific Urological Cancer Drugs Sales Quantity by Region (2019-2024) & (K Pcs)

Table 131. Asia-Pacific Urological Cancer Drugs Sales Quantity by Region (2025-2030) & (K Pcs)

Table 132. Asia-Pacific Urological Cancer Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 133. Asia-Pacific Urological Cancer Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 134. South America Urological Cancer Drugs Sales Quantity by Type (2019-2024) & (K Pcs)

Table 135. South America Urological Cancer Drugs Sales Quantity by Type (2025-2030) & (K Pcs)

Table 136. South America Urological Cancer Drugs Sales Quantity by Application (2019-2024) & (K Pcs)

Table 137. South America Urological Cancer Drugs Sales Quantity by Application (2025-2030) & (K Pcs)

Table 138. South America Urological Cancer Drugs Sales Quantity by Country (2019-2024) & (K Pcs)

Table 139. South America Urological Cancer Drugs Sales Quantity by Country (2025-2030) & (K Pcs)

Table 140. South America Urological Cancer Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 141. South America Urological Cancer Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 142. Middle East & Africa Urological Cancer Drugs Sales Quantity by Type (2019-2024) & (K Pcs)

Table 143. Middle East & Africa Urological Cancer Drugs Sales Quantity by Type (2025-2030) & (K Pcs)

Table 144. Middle East & Africa Urological Cancer Drugs Sales Quantity by Application (2019-2024) & (K Pcs)

Table 145. Middle East & Africa Urological Cancer Drugs Sales Quantity by Application (2025-2030) & (K Pcs)

Table 146. Middle East & Africa Urological Cancer Drugs Sales Quantity by Region (2019-2024) & (K Pcs)

Table 147. Middle East & Africa Urological Cancer Drugs Sales Quantity by Region (2025-2030) & (K Pcs)

Table 148. Middle East & Africa Urological Cancer Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 149. Middle East & Africa Urological Cancer Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 150. Urological Cancer Drugs Raw Material

Table 151. Key Manufacturers of Urological Cancer Drugs Raw Materials

Table 152. Urological Cancer Drugs Typical Distributors

Table 153. Urological Cancer Drugs Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Urological Cancer Drugs Picture
- Figure 2. Global Urological Cancer Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 3. Global Urological Cancer Drugs Consumption Value Market Share by Type in 2023
- Figure 4. Tablets Examples
- Figure 5. Injection Examples
- Figure 6. Global Urological Cancer Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
- Figure 7. Global Urological Cancer Drugs Consumption Value Market Share by Application in 2023
- Figure 8. Prostate Cancer Examples
- Figure 9. Bladder Cancer Examples
- Figure 10. Kidney Cancer Examples
- Figure 11. Testicular Cancer Examples
- Figure 12. Others Examples
- Figure 13. Global Urological Cancer Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
- Figure 14. Global Urological Cancer Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
- Figure 15. Global Urological Cancer Drugs Sales Quantity (2019-2030) & (K Pcs)
- Figure 16. Global Urological Cancer Drugs Average Price (2019-2030) & (USD/Pcs)
- Figure 17. Global Urological Cancer Drugs Sales Quantity Market Share by Manufacturer in 2023
- Figure 18. Global Urological Cancer Drugs Consumption Value Market Share by Manufacturer in 2023
- Figure 19. Producer Shipments of Urological Cancer Drugs by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2023
- Figure 20. Top 3 Urological Cancer Drugs Manufacturer (Consumption Value) Market Share in 2023
- Figure 21. Top 6 Urological Cancer Drugs Manufacturer (Consumption Value) Market Share in 2023
- Figure 22. Global Urological Cancer Drugs Sales Quantity Market Share by Region (2019-2030)
- Figure 23. Global Urological Cancer Drugs Consumption Value Market Share by Region

(2019-2030)

Figure 24. North America Urological Cancer Drugs Consumption Value (2019-2030) & (USD Million)

Figure 25. Europe Urological Cancer Drugs Consumption Value (2019-2030) & (USD Million)

Figure 26. Asia-Pacific Urological Cancer Drugs Consumption Value (2019-2030) & (USD Million)

Figure 27. South America Urological Cancer Drugs Consumption Value (2019-2030) & (USD Million)

Figure 28. Middle East & Africa Urological Cancer Drugs Consumption Value (2019-2030) & (USD Million)

Figure 29. Global Urological Cancer Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 30. Global Urological Cancer Drugs Consumption Value Market Share by Type (2019-2030)

Figure 31. Global Urological Cancer Drugs Average Price by Type (2019-2030) & (USD/Pcs)

Figure 32. Global Urological Cancer Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 33. Global Urological Cancer Drugs Consumption Value Market Share by Application (2019-2030)

Figure 34. Global Urological Cancer Drugs Average Price by Application (2019-2030) & (USD/Pcs)

Figure 35. North America Urological Cancer Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 36. North America Urological Cancer Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 37. North America Urological Cancer Drugs Sales Quantity Market Share by Country (2019-2030)

Figure 38. North America Urological Cancer Drugs Consumption Value Market Share by Country (2019-2030)

Figure 39. United States Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 40. Canada Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 41. Mexico Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 42. Europe Urological Cancer Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 43. Europe Urological Cancer Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 44. Europe Urological Cancer Drugs Sales Quantity Market Share by Country (2019-2030)

Figure 45. Europe Urological Cancer Drugs Consumption Value Market Share by Country (2019-2030)

Figure 46. Germany Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 47. France Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 48. United Kingdom Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 49. Russia Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 50. Italy Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 51. Asia-Pacific Urological Cancer Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 52. Asia-Pacific Urological Cancer Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 53. Asia-Pacific Urological Cancer Drugs Sales Quantity Market Share by Region (2019-2030)

Figure 54. Asia-Pacific Urological Cancer Drugs Consumption Value Market Share by Region (2019-2030)

Figure 55. China Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 56. Japan Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 57. Korea Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 58. India Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 59. Southeast Asia Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 60. Australia Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 61. South America Urological Cancer Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 62. South America Urological Cancer Drugs Sales Quantity Market Share by

Application (2019-2030)

Figure 63. South America Urological Cancer Drugs Sales Quantity Market Share by Country (2019-2030)

Figure 64. South America Urological Cancer Drugs Consumption Value Market Share by Country (2019-2030)

Figure 65. Brazil Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 66. Argentina Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 67. Middle East & Africa Urological Cancer Drugs Sales Quantity Market Share by Type (2019-2030)

Figure 68. Middle East & Africa Urological Cancer Drugs Sales Quantity Market Share by Application (2019-2030)

Figure 69. Middle East & Africa Urological Cancer Drugs Sales Quantity Market Share by Region (2019-2030)

Figure 70. Middle East & Africa Urological Cancer Drugs Consumption Value Market Share by Region (2019-2030)

Figure 71. Turkey Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 72. Egypt Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 73. Saudi Arabia Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 74. South Africa Urological Cancer Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)

Figure 75. Urological Cancer Drugs Market Drivers

Figure 76. Urological Cancer Drugs Market Restraints

Figure 77. Urological Cancer Drugs Market Trends

Figure 78. Porters Five Forces Analysis

Figure 79. Manufacturing Cost Structure Analysis of Urological Cancer Drugs in 2023

Figure 80. Manufacturing Process Analysis of Urological Cancer Drugs

Figure 81. Urological Cancer Drugs Industrial Chain

Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 83. Direct Channel Pros & Cons

Figure 84. Indirect Channel Pros & Cons

Figure 85. Methodology

Figure 86. Research Process and Data Source

I would like to order

Product name: Global Urological Cancer Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/G72CB540F61CEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G72CB540F61CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

